Giredestrant clinical trials
Also written GDC-9545 and RO7197597.
ClinicalTrials.gov finds 30 studies for giredestrant. How that becomes 22 here
Every study that search finds has been read, to see whether and how it gives giredestrant. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 30Found by its intervention search · See all 30 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 30 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 30Give giredestrant to participants
- −1Observe patients on it, or give it outside a trial
- −7Give it beside what is tested
- 22Test it: the count on this site
Get an email when these change. Save the giredestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 5
Hoffmann-La Roche (11) · Genentech, Inc. (6) · MedSIR (2) · ETOP IBCSG Partners Foundation (1) · Alliance Foundation Trials, LLC. (1) · Fondazione Oncotech (1)
Often tested with
Tested in the same studies.
Inavolisib (5) · Ipatasertib (3) · Ado-Trastuzumab Emtansine (2) · Atezolizumab (2) · Bevacizumab (2) · Cobimetinib (1) · Paclitaxel (1) · Olaparib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 8 most studied
New when their studies opened, with giredestrant beside them; studies of each.
Reaching primary completion within a year · 2
Studies that test giredestrant.
- Jul 2027A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerPhase 1 · Genentech, Inc.
- Jul 2027A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerPhase 2 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses giredestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 22
- A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)RecruitingPhase 3Genentech, Inc.NCT07541079Adherence and outcomes on switching to itWritten as GiredestrantReport a problem
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentRecruitingPhase 3Hoffmann-La RocheNCT07827573Adherence and tolerability, upfront or after a switchWritten as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759With targeted drugs in an umbrella study (MORPHEUS)Written as GiredestrantReport a problem
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190With inavolisib in some early-stage armsWritten as GiredestrantReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With abemaciclib in one endometrial cancer cohortWritten as GiredestrantReport a problem
- NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingPhase 2Fondazione OncotechNCT06259929With abemaciclib before surgeryReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04546009Against letrozole with palbociclib (persevERA)Written as GiredestrantReport a problem
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03332797First-in-human, alone or with palbociclibWritten as GDC-9545Report a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340With everolimus against physician's choice (evERA)Written as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996Adjuvant against physician's choice (lidERA)Written as GiredestrantReport a problem
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Added to Phesgo maintenance (heredERA)Written as GiredestrantReport a problem
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingPhase 2MedSIRNCT05708235With abemaciclib or inavolisib on ctDNA relapseWritten as GiredestrantReport a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Against fulvestrant with a CDK4/6 inhibitor (pionERA)Written as GiredestrantReport a problem
- A Study of Giredestrant in Participants With Grade 1 Endometrial CancerCompletedPhase 2Hoffmann-La RocheNCT05634499Alone in grade 1 endometrial cancerWritten as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingPhase 2Hoffmann-La RocheNCT04576455Against physician's choice of endocrine therapy (acelERA)Written as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342With abemaciclib in one ER-positive armWritten as GiredestrantReport a problem
- Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%CompletedPhase 2MedSIRNCT05659563Against tamoxifen before surgery in premenopausal womenWritten as GiredestrantReport a problem
- A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedPhase 2ETOP IBCSG Partners FoundationNCT05896566With or without triptorelin before surgery (PREcoopERA)Written as GiredestrantReport a problem
- A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerCompletedPhase 1Genentech, Inc.NCT03916744Before surgery at three dosesWritten as GiredestrantReport a problem
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing PotentialCompletedPhase 1Genentech, Inc.NCT04680273Radiolabelled dose and formulations in healthy womenWritten as [14C]-GDC-9545Report a problem
See all 22 studies that test giredestrant →
Tested on its own · 5 — no other medicine in its arm
- A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)RecruitingPhase 3Genentech, Inc.NCT07541079Adherence and outcomes on switching to itWritten as GiredestrantReport a problem
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentRecruitingPhase 3Hoffmann-La RocheNCT07827573Adherence and tolerability, upfront or after a switchWritten as GiredestrantReport a problem
- A Study of Giredestrant in Participants With Grade 1 Endometrial CancerCompletedPhase 2Hoffmann-La RocheNCT05634499Alone in grade 1 endometrial cancerWritten as GiredestrantReport a problem
- Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%CompletedPhase 2MedSIRNCT05659563Against tamoxifen before surgery in premenopausal womenWritten as GiredestrantReport a problem
- A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerCompletedPhase 1Genentech, Inc.NCT03916744Before surgery at three dosesWritten as GiredestrantReport a problem
Tested with established drugs · 10 — they are given beside it
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04546009Against letrozole with palbociclib (persevERA)Written as GiredestrantReport a problem
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03332797First-in-human, alone or with palbociclibWritten as GDC-9545Report a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340With everolimus against physician's choice (evERA)Written as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT04961996Adjuvant against physician's choice (lidERA)Written as GiredestrantReport a problem
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Added to Phesgo maintenance (heredERA)Written as GiredestrantReport a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Against fulvestrant with a CDK4/6 inhibitor (pionERA)Written as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Active, not recruitingPhase 2Hoffmann-La RocheNCT04576455Against physician's choice of endocrine therapy (acelERA)Written as GiredestrantReport a problem
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing PotentialCompletedPhase 1Genentech, Inc.NCT04680273Radiolabelled dose and formulations in healthy womenWritten as [14C]-GDC-9545Report a problem
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)CompletedPhase 2Hoffmann-La RocheNCT04436744Against anastrozole with palbociclib before surgery (coopERA)Written as GiredestrantReport a problem
- Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing PotentialCompletedPhase 1Genentech, Inc.NCT04274075Bioavailability and food effect in healthy womenWritten as GDC-9545 Tablet, Fasted: Treatment AReport a problem
Tested in a combination · 7 — another drug in the study is under test too
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759With targeted drugs in an umbrella study (MORPHEUS)Written as GiredestrantReport a problem
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190With inavolisib in some early-stage armsWritten as GiredestrantReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352With abemaciclib in one endometrial cancer cohortWritten as GiredestrantReport a problem
- NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingPhase 2Fondazione OncotechNCT06259929With abemaciclib before surgeryReport a problem
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingPhase 2MedSIRNCT05708235With abemaciclib or inavolisib on ctDNA relapseWritten as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342With abemaciclib in one ER-positive armWritten as GiredestrantReport a problem
- A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerCompletedPhase 2ETOP IBCSG Partners FoundationNCT05896566With or without triptorelin before surgery (PREcoopERA)Written as GiredestrantReport a problem
Beside a new treatment under test · 6 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with giredestrant: atirmociclib 3 · ipatasertib 1 · SGN-LIV1A 1 · selicrelumab 1 · sacituzumab govitecan 1 · inavolisib 1 · Vustanaciclib 1 · GDC-0587 1
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerNot yet recruitingPhase 3PfizerNCT07890597In every armGiven in both arms; atirmociclib is tested against placeboWritten as giredestrantReport a problem
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 2PfizerNCT04557449Partner of new atirmociclib in one armWritten as GiredestrantReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Partner of new inavolisib in some armsWritten as GiredestrantReport a problem
- A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast CancerNot yet recruitingPhase 1Genentech, Inc.NCT07867262Partner of new GDC-4198 in one armWritten as GiredestrantReport a problem
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingPhase 1/2Genentech, Inc.NCT07100106In every armPartner of new GDC-4198 in every armWritten as GiredestrantReport a problem
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerTerminatedPhase 1Genentech, Inc.NCT07214662Partner of new GDC-0587Written as GiredestrantReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
Observed · 1 — patients on it are followed, or it is given outside a trial
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call giredestrant · ClinicalTrials.gg INT001743
- MeSH (NLM) C000720132giredestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 28P3DU6DB3GIREDESTRANTConfirmed FDA, NLM
- NCI Thesaurus C147030GiredestrantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720132 | giredestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 28P3DU6DB3 | GIREDESTRANT | Confirmed FDA, NLM |
| NCI Thesaurus | C147030 | Giredestrant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.